TAS-102 Provides Survival Benefit in Refractory Colorectal Cancer
the Cancer Therapy Advisor take:
In patients with refractory colorectal cancer, TAS-102 was associated with a significant improvement in overall survival compared with placebo, a study published in the New England Journal of Medicine has shown.
For the double-blind study, researchers enrolled 800 patients with refractory colorectal cancer and randomly assigned them 2:1 to receive TAS-102 or placebo.
Results showed that the median overall survival was 5.3 months and 7.1 months in the placebo and TAS-102 groups, respectively (HR for death = 0.68; 95% CI: 0.58-0.81; P < 0.001).
In regard to safety, the most common adverse events associated with TAS-102 were neutropenia, leukopenia, and febrile neutropenia. One patient died as a result of TAS-102 treatment. Median time to worsening performance status was also 1.7 months longer in the TAS-102 arm than the placebo arm (HR = 0.66; 95% CI: 0.56-0.78; P < 0.001).
TAS-102 is an oral agent that combines trifluridine and tipiracil hydrochloride. Previous studies conducted mostly in Japan that it was effective in the treatment of patients with refractory colorectal cancer.
In patients with refractory colorectal cancer, TAS-102 was associated with a significant improvement in overall survival.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Research Indicates Imatinib Is Effective in Pediatric Patients With Chronic Phase CML
- Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer
- Research Advances for Mutant KRAS-Driven Lung Adenocarcinoma
- First-Line Atezolizumab Plus Bevacizumab Receives Breakthrough Therapy Designation for HCC
- Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy